CervoMed Inc., a clinical-stage biotechnology company, engages in the development and commercialization of drug treatments for neurodegenerative diseases. It develops neflamapimod, an orally administered small molecule brain penetrant for the treatment of dementia with Lewy bodies (DLB), Alzheimer's diseases, and brain stroke recovery. The company is based in Boston, Massachusetts.
Employees - 15,
CEO - Dr. John J. Alam M.D.,
Sector - Healthcare,
Country - US,
Market Cap - 96.43M
Altman ZScore(max is 10): 12.44, Piotroski Score(max is 10): 2, Working Capital: $39202328, Total Assets: $43081610, Retained Earnings: $-70731484, EBIT: -18227129, Total Liabilities: $3879282, Revenue: $5636221
AryaFin Target Price - $1.11 - Current Price $11.08 - Analyst Target Price $15.83
| Ticker | CRVO |
| Index | RUT |
| Curent Price | 11.08 |
| Change | -1.42% |
| Market Cap | 96.43M |
| Average Volume | 4.64M |
| Income | -16.29M |
| Sales | 9.74M |
| Book Value/Share | 4.50 |
| Cash/Share | 4.47 |
| Dividend Est | - |
| Dividend TTM | - |
| Dividend Ex-Date | - |
| Employees | 15 |
| Moving Avg 20days | 25.29% |
| Moving Avg 50days | 127.27% |
| Moving Avg 200days | 8.53% |
| Shares Outstanding | 8.70M |
| Earnings Date | Mar 17 BMO |
| Inst. Ownership | 17.08% |
| Price/Earnings | - |
| Forwad P/E | - |
| PE Growth | - |
| Price/Sales | 9.90 |
| Price/Book | 2.46 |
| Price/Cash | 2.48 |
| Price/FCF | - |
| Quick Ratio | 11.11 |
| Current Ratio | 11.11 |
| Debt/Equity | 0.00 |
| Return on Assets | -60.98% |
| Return on Equity | -69.95% |
| Return on Investment | -41.56% |
| Gross Margin | - |
| Ops Margin | -187.18% |
| Profit Margin | -167.29% |
| RSI | 60.40 |
| BETA(β) | -0.36 |
| From 52week Low | 515.56% |
| From 52week High | -57.25% |
| EPS | -2.02 |
| EPS next Year | -2.10 |
| EPS next Qtr | -0.64 |
| EPS this Year | 5.03% |
| EPS next 5 Year | 3.71% |
| EPS past 5 Year | 56.66% |
| Sales past 5 Year | 7.26% |
| EPS Y/Y | 53.38% |
| Sales Y/Y | 142.42% |
| EPS Q/Q | -91.86% |
| Sales Q/Q | -13.19% |
| Sales Surprise | 40.76% |
| EPS Surprise | -24.55% |
| ATR(14) | 2.06 |
| Perf Week | 16.88% |
| Perf Month | 415.35% |
| Perf Quarter | 396.86% |
| Perf Year | -47.31% |
| Perf YTD | 373.50% |
| Target Price | 15.83 |
AryaFin Engine© - An AI FinTech Venture - 2024-25 Disclaimer